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Madam Rector Magnificus, dear colleagues and students, dear friends and 
family, highly esteemed listeners, 
 
Today I am pleased to accept the chair Inborn metabolic diseases with focus on 
galactosemia. 
 
Imagine that you have just become the proud parent of a beautiful child. You dream of a 
wonderful future for your baby, but after a few days the baby becomes ill and then it 
becomes increasingly ill. Then you receive the news that your child has a hereditary 
metabolic disease. Your hopes and dreams are shattered. What do I do now? What is 
metabolism? What is this disease? What can be done about it? What impact does this have 
on the life of my child, and on our family? 
 
 
Hereditary metabolic diseases in general and galactosemia in particular 
 
Let's start by understanding what metabolism is. The word metabolism (from the Greek 
μεταβολισμός “metabolismos”) means change or transformation. It is the whole of 
biochemical processes that take place in our cells from which different chemical compounds 
originate that we call metabolites. 
 
In the cell, many chemical processes take place at the same time. This can be compared to a 
small but highly advanced and efficient chemical plant. This requires a tight coordination and 
regulation of all these processes in the different structures in the cell, where these processes 
take place. DNA plays a crucial role in this coordination, because it encodes all proteins that 
are involved in the chemical processes and from which the cell structures are made of. The 
most important processes which take place in the cell are composition and refinement, 
transport, energy production and finally the breakdown of the building blocks of the cell. In 
essence, there are four types of building blocks from which all living organisms are made: 
amino acids (proteins), nucleotides (DNA), carbohydrates and fats (both energy). 
 
Almost every chemical reaction in the cell needs an enzyme to allow the chemical reaction 
to take place quickly enough so that we can remain alive. The sequence of steps in which a 
chemical substance, with the help of enzymes, is converted into other chemical substances, 
is what we call a metabolic pathway. Hereditary metabolic diseases are caused by 
abnormalities in these metabolic pathways due to errors in the DNA. 
 
There are a lot of metabolic pathways, all with many steps. You might wonder: why is it so 
complicated? Many steps mean a lot of intermediates (metabolites), which are also needed 
for other metabolic pathways. Many steps also mean that the cell does not use more than it 
is necessary, that there is no waste. An error can occur in each step, which is why we must 
deal with many different errors that can lead to a variety of hereditary metabolic diseases, 
hundreds of them, with widely differing forms of expression and severity. 
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Every year, 800 children are born in The Netherlands with one of these disorders. There are 
many families with children with hereditary metabolic diseases. For some diseases, there is 
still no treatment and many children die due to complications. For other diseases, there is a 
treatment, but this treatment is not able to completely prevent the symptoms of the 
disease, as a result of which patients, their families and our society suffer the heavy 
consequences. The care for these diseases is concentrated in University Medical Centers 
(UMC) because it requires special expertise, knowledge and infrastructure. 
 
 
 
 
 
 
Understanding errors in hereditary metabolism 
 
An example of a metabolic pathway is galactose metabolism. Galactose is a sugar present in 
many nutrients, but especially in animal milk in the form of lactose or milk sugar. Once in the 
cell, galactose is converted into energy in several steps and in other substances that are 
necessary for complex molecules. Errors in the DNA during the different steps, cause the 
group of diseases called galactosemia. The most common is classic galactosemia. In this 
disease, an error occurs in the piece of DNA that contains the recipe for making the GALT 
enzyme. But, how was this disease discovered? 
 
The first description was made in 1908 (Von Reuss). A newborn was described with the acute 
picture of classic galactosemia: nutritional problems, poor growth, vomiting, jaundice, 
irritability, enlarged liver and cataracts, among other things. In the next decade, it was 
documented the presence of excess galactose in the urine of an also affected baby (Göppert 
1917). In 1935, it was described the case of an infant with high level of galactose in blood 
and urine (blood: hypergalactosemia and urine: galactosuria) which responded well to a diet 
with lactose restriction (no breastfeeding/animal milk) (Mason and Turner 1935). Many 
years later, in 1956, it was discovered that galactose 1-phosphate was increased in the red 
blood cells of these patients (Schwarz et al.) and GALT was identified as the underlying 
enzyme that did not work well (Isselbacher et al. 1956). It was not until 1988 that the GALT 
gene was identified (Reichardt and Berg 1988). 
 
But what exactly happens with galactose in our cells? For the understanding of metabolism, 
we always must go back to biochemistry. It was Federico Leloir who clarified the steps in this 
route. He was a medical student who wanted to better understand physiology and began 
studying biochemistry. His work has taught us that the sugar galactose is first converted into 
galactose-1-phosphate and then in a ping-pong reaction is converted to glucose-1- 
phosphate and UDP-galactose by means of UDP-glucose. While glucose-1-phosphate is used 
as a source of energy, UDP-galactose and UDP-glucose are sugar donors for other reactions. 
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Figure 1: Galactose metabolic pathway: GALK1-, GALT-, GALE-enzyme representation. 
GALK1: galactokinase, GALT: galactose 1-phosphate uridylyltransferase, GALE: UDP-
galactose 4-epimerase. 
 
 
With this knowledge, we can understand why newborns with errors in this metabolic 
pathway develop high levels of galactose in blood and urine. The enormous amount of 
galactose present in breast milk or bottle feeding cannot be processed and it is increased 
body fluids. There is too much of certain substances and a shortage of other ones and this 
leads to the symptoms of the disease. By adjusting the diet, the neonatal clinical picture 
clears up and the children do well until they are slightly older. Between 1970 and 1990 it 
became increasingly clear that diet solves the serious clinical picture of the newborn, but it 
does not prevent the appearance of complications. Unfortunately, despite their diet, most 
patients develop complications that especially affect the brain and ovaries, resulting in 
cognitive, behavioral and neurologic problems, in both men and women (85%), and 
subfertility in women (80%). In addition, patients are at risk of suffering reduced bone 
density (26%) (Source: International Galactosemia Patient Registry). 
 
 
This means that new and better 
treatments are needed. This 
requires more understanding about 
the course and mechanisms of the 
disease. As our understanding of these diseases increases, we can develop better diagnostic 
tools and investigate new therapies aimed to improve the future of the patients and their 
families. We can start treating patients better and treat what was untreatable. However, this 
is a process that depends strongly on collaboration, open science and available resources. 
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Understanding the importance of collaboration 
 
In the past, clinicians and researchers worked mainly from their own perspective. Nowadays, 
the boundaries between the various disciplines are disappearing. Integrated theories about 
what the relationship is at different levels between processes and how they influence each 
other, can only be achieved by joining forces and multidisciplinary and interdisciplinary 
approaches. Understanding in that sense is a requirement for progress. Collaboration 
requires an open attitude, trust, transparency, not to envy each other, parking the egos 
somewhere where they do not stand in the way for collaboration and keeping in mind the 
common goal. This is what we must continue to realize and transfer to the new generations. 
Joining forces is not a choice, but a requirement. 
 
Based on the conviction of the importance of collaboration, in 2009 I started exploring the 
possibilities of establishing an international galactosemia network. In 2009 and 2011, I 
organized the first and second international galactosemia workshop at the Medical Center of 
Maastricht University, with subsidies from the Dutch Organization for Scientific Research 
(NWO), and in 2012 the galactosemia network (GalNet) was established. 
 
In the meantime, professionals from 20 different countries are participating. GalNet was 
founded with support of the Dutch and European Galactosemia Patient Associations. 
Networks of professionals are crucial but require the networks of patients. The existence of 
the Dutch Galactosemia Association, under the leadership of Jeroen van Bruggen and Karen 
't Hoofd, and the European Galactosemia Association with Jeroen and Maaike van Kempen 
as president and vice president, is very important for the treatment, monitoring and 
research of galactosemia.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Galactosemia Network (GalNet). 
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GalNet focuses on the promotion of education, research, diagnosis, treatment and aftercare 
of patients with galactosemia through close cooperation between clinicians, researchers and 
nutritionists, and patient organizations. Since the formation, we have achieved together 
several important goals and we are fully engaged on the road to achieve optimum care and 
treatment. What is the power of such a network? What can we do together? Let me give a 
few examples. 
 
 
 
Figure 3: GalNet focuses on education, research, diagnosis, treatment and follow-up. 
 
 
In 2017, guidelines for diagnosis, treatment and follow-up of patients with the most 
common form of galactosemia were published under the inspiring guidance of my colleague 
Dr. Annet Bosch of Amsterdam UMC. The next step is that these guidelines are known and 
used among the involved professionals and patients. Only publishing is not enough. We are 
now working on a strategy for dissemination and implementation led by a colleague from 
Denver and the vice president of the European Galactosemia Association Maaike van 
Kempen. 
 
In 2019 the natural course of classic galactosemia based on data from 509 patients from 32 
centers in 15 different countries from the international patient registry that is coordinated 
by me is going to be published. For a rare disease, these are big numbers. The conditio sine 
qua non for the development of new treatments is to know the natural course of a disease 
based on a large number of data. 
 
In addition, we are fully engaged in the development of new therapies for galactosemia 
using the newest insights and technologies in our field. With this knowledge and resources, 
and together with other leading metabolic centers, we can move forward to obtain better 
treatments. Important recent contributions from our MUMC+ galactosemic research team 
have been 1- the development of a zebra fish animal model for this disease and 2- the 
identification of the neuronal networks related to the cognitive problems of these patients. 
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How might a new treatment look like? Let me give a few examples of promising approaches 
we are currently working on. The first one is the correction of the DNA error using mRNA 
therapy. This is a form of gene therapy, in which instead of directly repairing the error, the 
correct recipe is offered to the cell so that it can produce the specific enzyme. mRNA, or 
messenger RNA, is RNA that has been transcribed nucleotide by nucleotide from a gene. 
Based on the nucleotide sequence in this mRNA, a protein of amino acids is composed. An 
error in the GALT gene means that the mRNA contains a different nucleotide sequence. This 
results in a GALT enzyme with a wrong amino acid composition and, therefore, it does not 
function properly. By administering the correct mRNA, we bridge the defect. The second one 
is the improvement of the stability and the efficacy of the GALT enzyme by adding small 
pharmacological molecules. Due to errors in the GALT gene an enzyme is made that is much 
less stable, and the addition of pharmacological molecules can be helpful. The effect of both 
strategies in our zebra fish model will provide essential information. The existence of GalNet 
and Patient Registry, together with the European Patient Association constitute a great 
platform to later translate the preclinical results into the clinical phase. 
 
Another promising approach is noninvasive brain stimulation (NIBS) in which alternating 
current is administered via electrodes to neural networks in order to modulate them with a 
favorable effect. The latter is the result of a wonderful collaboration with Prof. Dr. 
Bernadette Jansma and Dr. Teresa Schuhmann from the Maastricht Brain Imaging Center 
(M-Bic). 
 
According to MUMC+ Innovation Circle, with this we are acquiring new knowledge and 
putting it into practice, create value and promote the health of patients with hereditary 
metabolic diseases. 
 
The foregoing would not have been possible without joining forces. These partnerships are 
not always easy, people, interpersonal relationships and divergent interest can continue to 
stand in the way of work. The medication for this is to keep the common goal in mind and 
hope that everyone takes the medication consistently. 
 
As a metabolic center we see a very wide spectrum of metabolic diseases. There is more 
good news for this whole group. Recently, it was established United for Metabolic Diseases 
(UMD), a great initiative of our colleagues from Amsterdam UMC (Dr. Clara van Karnebeek 
and Prof. Dr. Hans Waterham). This is a unique collaboration between doctors and 
researchers from six different UMCs, including MUMC+, and the patient association 
"Association for Children and Adults with Metabolic Diseases", to accelerate and improve 
diagnostics and treatment. Financing is possible through the Stichting Meta Kids and the 
Dutch lottery VriendenLoterij. This initiative is also supported by Number 5 Foundation, 
which was founded by Princess Laurentien and her husband, to provide innovative social 
projects a platform to realize shared ambitions. 
 
Last year, it was also established an important partnership for our hospital: The Academic 
Alliance between MUMC+ and Radboudumc. The clinical genetics departments with the 
laboratory of metabolic diseases and colleagues from the transmural metabolic laboratory in 
Nijmegen are working closely to create a virtual center for diagnostic. This is a considerable 
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improvement in efficiency and use of expensive infrastructure. For the clinical part, pediatric 
metabolic diseases, we are working to intensify our collaboration. For research we have 
started with the use of our shared interest in nucleotide sugars and are working with Prof. 
Dr. Dirk Lefeber to clarify how deviations relate to disease symptoms. 
 
Let me also give you an example of how we work in the clinic. A boy is admitted with 
complaints after practicing sport intensively. He has cola-colored urine and enormous pain in 
his muscles. These complaints are consistent with muscle breakdown. Because the kidney is 
threatened, the necessary measures are taken to prevent the threat of kidney damage and 
parallel to this a diagnostic work-up is used in which a hereditary metabolic disease is 
considered. We know this presentation, among other things, from defects in the oxidation of 
long chain fatty acids. These are the fats present in our foods that we metabolize to release 
energy.  
 
A few diagnostic tests are run and from the results we can conclude that there is indeed a 
specific defect in the metabolism of long chain fatty acids. We can do this diagnostic at 
metabolite level quickly, in several hours. Confirmation at enzymatic and genetic level takes 
longer, but it is not necessary for the acute situation. This result means that in addition to 
the protection of the kidney, enough energy in the form of sugar via infusion is to be given to 
stop the disease process. This diagnostic gives clarity and opens the doors to an adequate 
treatment. In order to run smoothly, this process requires that all participants have the right 
knowledge, that there is the necessary infrastructure (think, for example, of the metabolic 
laboratory), an excellent communication between all participants, including patient and 
family, and a flawless logistics. 
 
 
Understanding that reallocation of resources is necessary 
 
The great diversity, complexity and rarity of hereditary metabolic diseases requires more 
focused attention and financial support of the costly infrastructure and scientific research. 
This is necessary to improve the prospects for patients and their families over the coming 
years. In our center, the number of clinicians involved in hereditary metabolic diseases is 
very low. The number of diagnosed patients with these diseases is increasing and also the 
number of patients who survive the disease and become a chronic patient. In addition, due 
to the expansion of neonatal screening in 2007 in several metabolic diseases it has been a 
steady increase in the number of diagnosed patients. The upcoming extra expansion will 
only strengthen this. This is a huge field of tension. Why should we spend so much money 
with neonatal screening to find patients, and invest so little in the long-term care of these 
people? Due to neonatal screening and that treatment is improving, we are constantly faced 
with new questions. With the new partnerships we will reduce our vulnerability. However, in 
order to continue these partnerships, it is also necessary to distribute the existing resources 
in such a way that we can also treat optimally patients with this group of diseases. 
 
Patients with rare hereditary metabolic diseases have the same right to optimal care as 
patients with more common diseases. Many of the great advances that have been made in 
medicine can be traced back to the understanding of hereditary metabolism. Nowadays, 
societal impact is used as one of the indicators to finance research.  
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In our socio-economic driven model, this makes it relatively easy for many common diseases 
to win the competition. But if we go back to the beginning of my lecture, and you are the 
parent of the baby with a hereditary metabolic disease, you also want that the treatment is 
optimal. For you it is not relevant that it is a rare disease, but that it is your child with the 
right to optimal care.  
 
The diseases individually are rare but as a group are common. In recent years, these diseases 
are fortunately more often on national and international agendas but there is still much 
more to be achieved. Many of the principles that have been investigated and applied in my 
field, are highly relevant for more common clinical pictures. 
 
 
Understanding the need for education 
 
If you are the parent of the sick baby with whom I started my lecture, you expect that the 
doctor will recognize the symptoms as possibly fitting in a hereditary metabolic disease and 
that appropriate action is taken promptly. However, this presupposes that, ideally, the 
physician has already been in contact with this group of diseases in the medical curriculum 
during his studies of medicine. Unfortunately, this is not always the case. These diseases are 
very unknown, usually people don’t think about them or when they think about them it is 
already too late. Here is for universities, as responsible for medical curricula, the task to pay 
more attention to biochemistry and hereditary metabolic diseases. Taking note of the 
importance of this is essential for this group of diseases that are not sufficiently known and, 
therefore, are inadequately recognized. Many of us working as a university lecturers should 
take the responsibility to ask for attention and come up with proposals in order to 
implement this education. At Maastricht University an optional block on hereditary 
metabolic diseases has been added to the curriculum of medicine for students in the 2nd 
year, which is a good start. 
 
It is important to give the new generation of medical professionals the knowledge about 
hereditary metabolic diseases. However, it is also equally important that experienced 
doctors, from general practitioners to academic medical specialists, can recognize this group 
of diseases. 
 
Women at the top 
 
As a female professor I want to stand still for a moment upon the matter of women at the 
top. A few years ago, I followed at the MUMC+ a trajectory for female talent. It is important 
that organizations support this kind of initiatives. Female talent is there, not always clearly 
visible, but it is findable. As a doctor, researcher, teacher and now, as a professor, I try to be 
a role model for many female talented colleagues, PhDs and students. At MUMC+ and UM I 
have many women who are role models for me, and who have inspired me and continue to 
inspire me in my career. Waste is sin, so let us strive not to waste female talent, we will all 
benefit from it. If we want to achieve this, women themselves will also need to change their 
way of thinking. 
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